What question did this study set out to answer?

The study aims to evaluate the safety and effectiveness of adjuvant imatinib treatment in reducing recurrence after GIST resection.

May 15, 2026Cancer MedicineOpen Access

Adjuvant Imatinib for Patients Resected for GIST : A Quality Assurance Study

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study assesses adjuvant imatinib safety and recurrence in resected GIST patients, indicating acceptable tolerability.

The study aims to evaluate the safety and effectiveness of adjuvant imatinib treatment in reducing recurrence after GIST resection.
Retrospective quality assurance study reviewing the treatment provided from January 2019 to December 2023.
Included 65 eligible patients following resection of GIST, after excluding six due to short follow-up.
Primary focus on safety, with secondary endpoints on recurrence-free survival and overall survival.
60% of patients reduced imatinib dosage due to toxicity, with 17% requiring treatment interruption.
23% of patients experienced relapse with a median time from diagnosis to recurrence of 4.5 years.
No significant difference in recurrence rates among those with dosage reduction or interruption.

Mohammad et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark